

This is a repository copy of *Pelvic re-irradiation using stereotactic ablative radiotherapy* (SABR): A systematic review.

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/123302/

Version: Supplemental Material

Article:

Murray, LJ orcid.org/0000-0003-0658-6455, Lilley, J, Hawkins, MA et al. (3 more authors) (2017) Pelvic re-irradiation using stereotactic ablative radiotherapy (SABR): A systematic review. Radiotherapy and Oncology, 125 (2). pp. 213-222. ISSN 0167-8140

https://doi.org/10.1016/j.radonc.2017.09.030

© 2017 Elsevier B.V. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: https://creativecommons.org/licenses/

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



Table 1. Remaining normal tissue doses for SABR small bowel re-irradiation based on variety of initial radiotherapy normal tissue doses and variety of cumulative constraints (based on $\alpha/\beta=3Gy$)

Possible dose received by normal tissues at first irradiation	No. fractions	Dose per fraction	EQD2 (α/β=3Gy)	Remaining dose constraint for 5 fraction SABR based on Abusaris et al cumulative constraints ^{20§}	Remaining dose constraint for 5 fraction SABR based on conventional first irradiation constraints used cumulatively, assuming no recovery)*	Remaining dose constraint for 5 fraction SABR based on conventional first irradiation constraints used cumulatively, assuming 50% recovery of original dose*	AAPM report constraints for 5 fraction pelvic SABR as first irradiation, included for comparison only ²⁹
Small bowel							
30	15	2.00	30.00	37.8 to 10cm ³	18.4 max point	24.8 max point	19.5 to < 5cm ³ / 35 max point**
34	15	2.27	35.81	36.2 to 10cm ³	15.4 max point	23.7 max point	19.5 to < 5cm ³ / 35 max point**
34	28	1.21	28.66	38.2 to 10cm ³	19.1 max point	25.1 max point	19.5 to < 5cm ³ / 35 max point**
42	25	1.68	39.31	35.2 to 10cm ³	13.4 max point	23.0 max point	19.5 to < 5cm ³ / 35 max point**
45	25	1.80	43.20	34.0 to 10cm ³	11.0 max point	22.2 max point	19.5 to < 5cm ³ / 35 max point**
50.4	28	1.80	48.38	32.5 to 10cm ³	7.1 max point	21.1 max point	19.5 to < 5cm ³ / 35 max point**
50	25	2.00	50.00	31.9 to 10cm ³	5.6 max point	20.7 max point	19.5 to < 5cm ³ / 35 max point**
54	28	1.93	53.23	30.9 to 10cm ³	2.0 max point	20.0 max point	19.5 to < 5cm ³ / 35 max point**
70	39	1.79	67.13	26.1 to 10cm ³	Nil remaining	16.6 max point	19.5 to < 5cm ³ / 35 max point**
78	39	2.00	78.00	21.8 to 10cm ³	Nil remaining	13.6 max point	19.5 to < 5cm ³ / 35 max point**
80	39	2.05	80.82	20.5 to 10cm ³	Nil remaining	12.8 max point	19.5 to < 5cm ³ / 35 max point**

[§] Abusaris et al cumulative constraints²⁰ small bowel: 110Gy (as EQD2, α/β =3), dose to no more than 10cm³

^{*}Conventional constraints: small bowel: e.g. maximum point dose 55Gy²⁵, based on 28 fraction treatment;

^{**}AAPM report constraints are those for ileum and jejunum max: maximum

Table 2. Suggested pragmatic conservative approach for organ at risk constraint definition for SABR re-irradiation

Organ at risk constraint determination									
First choice ('best case scenario')		Second choice ('pragmatic compromise')							
Subtract previous dose from traditional constraint, no repair permitted	If first choice constraints not feasible	Subtract previous dose from traditional constraint, allowing degree of repair	AND	Do not exceed AAPM report constraints for first irradiation ²⁹ , nor Abusaris et al ²⁰ constraints					